glp-1 weight loss slidell for obesity The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 Before & After Semaglutide GLP-1

Other precautions include monitoring for diabetic retinopathy if blood glucose falls rapidly, maintaining adequate hydration, and avoiding use in pregnancy or breastfeeding unless specifically advised by a specialist

This analysis uses 2023 Medicare claims for traditional Medicare, Medicare Advantage encounter data, and Part D prescription drug event data to estimate the total number of Medicare beneficiaries with obesity or overweight, the number of Part D enrollees who met the Bridge eligibility criteria in 2023, and those who met the Bridge clinical criteria but who also had diagnoses recorded in claims or encounter data that would qualify for Part D coverage of GLP-1s (type 2 diabetes, OSA, or MASH) or who had a GLP-1 Part D-covered prescription during the year, either of which would make them ineligible for Bridge (see Methods)

" How They Confirmed It Two additional experiments are what elevate this from an observed correlation to a proposed mechanism, and they are worth describing because they show what a well-built animal study looks like

Telehealth prescribing of GLP-1 medications is legal in most US states when: The prescribing provider is licensed in your state of residence (not just any state) The provider conducts a compliant clinical evaluation asynchronous (form-based) consultations meet this standard in most states The prescription is issued through a certified, Surescripts-registered electronic prescribing system The provider makes an independent clinical judgment not simply rubber-stamping patient requests GLP-1 medications are not controlled substances, which means prescribing rules are less restrictive than for medications like testosterone